GanglioCombi-Light
… the expert’s choice: for basic screening

A Microtiter plate of GanglioCombi-Light is coated as follows:
Fig 1a

As an example, a GanglioCombi-Light could be used as shown in Fig 1b. Doing an IgG and IgM profile per patient there is capacity for 12 patients per plate.
Fig 1b

anti-GM1 antibodies: anti-IgG GM1 antibodies are implicated in the pathogenesis of Guillain-Barré Syndrome (GBS) and anti-IgM GM1 antibodies in multifocal neuropathy (MMN) and motor neuron diseases (MND). anti-IgM GM1 antibodies may be present as monoclonal IgM paraprotein or as a polyclonal IgM. Polyclonal IgG may be detected in patients with motor neuropathies. High GM1 antibody titers may be detected in association with in Guillain-Barré Syndrome (GBS) following Campylobacter jejuni infection. The fact that GM1 is the only common Glycolipid antigen reactive with all of the GM1 antibodies found in motor nerve disorders suggests that it is the relevant target antigen in neural tissue.
Anti-GD1b antibodies: Reactivity against Gangliosides containing disialosyl groups, particularly GD1b, has been reported in isolated cases of acute and chronic idiopathic ataxic neuropathies (SAN).
The clinical picture comprises a chronic neuropathy with marked sensory ataxia and areflexia and with relatively preserved motor function in the limbs. In addition many patients have preserved motor function. When present in their entirety, these clinical features are described under the acronym CANOMAD (chronic, ataxic, neuropathy, opthalmoplegia, IgM paraprotein, cold agglutinins, disialosy antibodies).
Anti-GQ1b antibodies: Anti- IgG GQ1b antibodies are closely associated with Miller-Fisher syndrome (MFS), which is discussed to be a variant of Guillain-Barré syndrome. Up to 100% of MFS patients have these antibodies. Anti-GQ1b antibodies decay rapidly with clinical recovery and usually are not found in normal and disease control samples. The close serologic-clinical association make anti-GQ1b antibodies in suspected cases of MFS a useful diagnostic marker for physicians with therapeutic significance.
Product Information
| GanglioCOMBI-LIGHT | |
|---|---|
Method |
ELISA |
Time to results |
4.5 h |
Sample Type |
20 µl serum (1:50) |
Standard range |
quantitative |
Isotypes |
IgG and gM |
Order code |
EK-GCL-GM 2x12 profiles |
| CE |
| DOWNLOADS | ||||
Instruction
|
Clinical Information |
Technical Information |
||
English |
[PDF 0.3MB] | |||
Deutsch |
||||
Francais |
||||
Italiano |
||||
* Multilingual document [EN, DE, FR, IT, ES]
Contact
Baselstr. 55
CH-4124 Schönenbuch
Switzerland
Fon: +41 61 487 12 12
Fax: +41 61 487 12 34
info@buhlmannlabs.ch
Your local distributor
Order
About us
Job opportunities
Search
News
NEW OWN CALPROTECTIN REIMBURSEMENT POSITION IN SWITZERLAND
BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimb more
New Seegene DPO Movie showing how this unique and proprietary technology is working to allow innovative multiplexing.
The unique and proprietary DPO™(Dual-Priming-Oligonucleotide) technology is the corner stone for all of the Seegene products, and it is the key to achieve more
New EntroGen BRAF test (V600E/K/D) for the detection of important mutations found in melanoma on your real-time PCR instrument.
EntroGen has a new BRAF test that detects, beside the V600E mutation, also the V600K and the V600D, which are important mutations found in melanoma. more
BÜHLMANN innovations and news at the JIB
At the JIB Congress in Paris, 8th – 10th November 2011, BÜHLMANN presents the MDx products of EntroGen and AutoGenomics as well as new developments of its more
BÜHLMANN Core | BÜHLMANN Molecular | BÜHLMANN Medical | Customer Relations | About Us |
Contact |
